Background Ebola virus disease (EVD) is a highly lethal condition for which no specific
treatment has proven efficacy. In September 2014, while the Ebola outbreak was at its peak …

Summary Background By January, 2016, all known transmission chains of the Ebola virus
disease (EVD) outbreak in west Africa had been stopped. However, there is concern about …

Background Artemether–lumefantrine and artesunate–amodiaquine are used as first-line
artemisinin-based combination therapies (ACTs) in west Africa. Pyronaridine–artesunate …

Objective To synthesise the evidence on pregnancy and childbirth after repair of obstetric
fistula in sub‐Saharan Africa and to identify the existing knowledge gaps. Methods A …

Background Sparse data on the safety of pyronaridine-artesunate after repeated treatment of
malaria episodes restrict its clinical use. We therefore compared the safety of pyronaridine …

Introduction Learning is a key attribute of a resilient health system and, therefore, is central
to health system strengthening. The main objective of this study was to analyse how …

The 2014–2015 Ebola virus disease (EVD) outbreak was unique in geography and extent,
with most of the 28610 cases and 11308 deaths, including among healthcare workers …

To date there are no approved antiviral drugs for the treatment of Ebola virus disease (EVD).
Based on our in vitro evidence of antiviral activity of interferon (IFN)-ß activity against Ebola …

Background In 2015, the laboratory at the Ebola treatment center in Coyah, Guinea,
confirmed Ebola virus disease (EVD) in 286 patients. The cycle threshold (Ct) of an Ebola …

In this paper we report the synthesis and antimalarial properties of two series of
fluoroalkylated γ-lactams derived from 4-aminoquinoline as potent chemotherapeutic agents …